Coronavirus company news summary – UK’s RECOVERY trial starts studies in Indonesia and Nepal – Novavax signs up to the COVAX facility

19 February 2021 (Last Updated February 19th, 2021 10:19)

19 February 2021

The UK‘s RECOVERY trial is now going global; Indonesia and Nepal are the first countries to join. Launched in the UK in March 2020 to investigate new treatments for Covid-19, the RECOVERY trial is open to all NHS patients with the viral disease. The first patients have been recruited for the international study. The RECOVERY trial has already shared positive results for six of the treatments studied,  including dexamethasone and tocilizumab.

Researchers from the British Columbia Centre for Disease Control and Institut National de Sante Publique du Quebec in Canada have announced that the second dose of Pfizer/BioNTech’s Covid-19 vaccine could be delayed to extend supply to all priority groups. This is because the vaccine had an efficacy of up to 92.6% between the first and second doses, according to documents submitted to the US Food and Drug Administration (FDA). The researchers published their conclusion in a letter in the New England Journal of Medicine.

Novavax has signed a Memorandum of Understanding (MOU) with Gavi, the vaccine alliance, to supply 1.1 billion cumulative doses of NVX-CoV2373, the company’s recombinant protein-based Covid-19 vaccine candidate, for the COVAX facility. The vaccine doses are expected to be manufactured and distributed across the world by Novavax and the Serum Institute of India.

Pfizer and BioNTech have dosed the first participants in a global Phase II/III study to assess their Covid-19 vaccine in healthy pregnant women aged over 18. The randomised, placebo-controlled trial will assess the safety, immunogenicity, and tolerability of the vaccine to prevent Covid-19 in 4,000 healthy women who are between 24 and 34 weeks pregnant.